Journal
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Volume 39, Issue 11, Pages 1618-1624Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/03639045.2012.727828
Keywords
Neurotoxin; chitosan; PLA nanoparticles; pharmacokinetics; intranasal administration; microdialysis
Categories
Funding
- National Natural Science Foundation of China (NSFC) [81072584]
Ask authors/readers for more resources
Context: Neurotoxin (NT), an analgesic peptide which was separated from the venom of Naja naja atra, is endowed an exceptional specificity of action that blocks transmission of the nerve impulse by binding to the acetylcholine receptor in the membrane. However, it has limited permeability across the blood-brain barrier (BBB). Objective: The purpose of this study was to encapsulate NT within polylactic acid (PLA) nanoparticles (NPs) modified with chitosan (NT-PLA-cNPs) and to evaluate their brain pharmacokinetic behaviors after intranasal (i.n.) administration using a microdialysis technique in free-moving rats. Methods: NT-PLA-cNPs (NT labeled with fluorescein isothiocyanate) were prepared and characterized. Then, NT-PLA-cNPs were i.n. administered to rats and the fluorescence intensity in the periaqueductal gray (PAG) was monitored for up to 480 min, with NT-PLA-NPs and NT solution as control groups. Results: The NPs prepared were spherical with a homogenous size distribution. The mean particle size, zeta potential, and entrapment efficiency were 140.5 +/- 5.4 nm, +33.71 +/- 3.24 mV, and 83.51 +/- 2.65%, respectively. The brain transport results showed that T-max of NT-PLA-cNPs was equal with that of NT-PLA-NPs after i.n. administration (150 min). The C-max and AUC(0-8 h) of each group followed the following order: NT-PLA-cNPs > NT-PLA-NPs. The corresponding absolute bioavailability (F-abs) of NT-PLA-cNPs was about 151% with NT-PLA-NPs as reference preparations. Conclusion: These results suggest that NPs modified with chitosan have better brain targeting efficiency and are a promising approach for i.n. delivery of large hydrophilic peptides and proteins in improving the treatment of central nervous system (CNS) disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available